Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07625592
Active, not recruiting Observational

Co-design of an AI Rehabilitation Program for Children With Borderline Intellectual Disorder

NCT07625592 · tracked via the Priya Life Science South Korea tracker
Sponsor
Samsung Medical Center
Phase
Observational
Started
2026-04-24
Last updated
2026-06-04

Condition(s) studied

Borderline Intellectual Functioning (BIF)Intellectual Disability

Investigational drug(s) / intervention(s)

Tablet-Based AI Cognitive and Language Rehabilitation Program

Tablet-Based AI Cognitive and Language Rehabilitation Program: A tablet-based artificial intelligence (AI) cognitive and language rehabilitation program previously experienced by children with borderline intellectual disorder. The study collects user and provider experiences through interviews and collaborative workshops to support experience-based co-design and program improvement.

Study summary

Co-design of an AI Rehabilitation Program for Children With Borderline Intellectual Disorder

Eligibility

Sex
ALL
Min age
7 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * School-aged children aged 7 to under 16 years with borderline intellectual disorder who have experienced the tablet-based AI cognitive and language rehabilitation program at least once * Legal guardians of eligible children * Developers of the AI rehabilitation program or professionals with expertise in cognition, language, learning, or rehabilitation for children with borderline intellectual disorder Exclusion Criteria: * Individuals who are unable to participate in interviews or workshops due to communication difficulties or inability to provide informed consent/assent

Primary outcome measure(s)

  • Qualitative Themes Regarding Participant Experiences with the AI Rehabilitation Program — Once per participant/professional during the interview or workshop session conducted post-intervention (overall data collection through December 2026).
    Qualitative themes regarding participant experiences with the tablet-based AI cognitive and language rehabilitation program will be identified. In-depth interviews will be conducted with users with borderline intellectual functioning and their legal guardians to explore usability and satisfaction. Additionally, focus group discussions with developers and clinical professionals will be held to gather multidisciplinary insights. All qualitative data will be analyzed using qualitative content analysis to extract key core themes. Therefore, there is no quantitative scale used. Results will be reported as identified thematic categories.

Trial sites (1)

FacilityCityRegionStatus
Samsung Medical Center Seoul Seoul

More Samsung Medical Center trials in South Korea

IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute MI Recruiting
Genomic Profiling of Pancreatic Cystic Tumors Starting soon
Head and Neck Cancer Omics/Integrated Precision Medicine (HOPE) Recruiting
Korean Stroke Cohort for Functioning and Rehabilitation-II Active, not recruiting
Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07625592 on ClinicalTrials.gov ↗ ← All trials in South Korea